{"date":"2025-11-19","count":10,"source":"公開資訊觀測站（MOPS）","attribution":"引用請註明：Drugnews 事實帳本（https://drugnews.com.tw/filings/）與公開資訊觀測站原始公告","records":[{"id":"tw-4745-2025-11-19-1808-hiy2h","company_id":"4745","company":"合富-KY","market":"上櫃","industry":"生技醫療","date":"2025-11-19","time":"18:08:04","subject":"代重要子公司合富（中國）醫療科技股份有限公司公告2025年第一次股東臨時會決議事項","clause":"第18款","fact_date":"2025-11-19","cite_as":"公開資訊觀測站重大訊息：合富-KY（4745），2025-11-19 18:08，「代重要子公司合富（中國）醫療科技股份有限公司公告2025年第一次股東臨時會決議事項」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6620-2025-11-19-1729-jj47v4","company_id":"6620","company":"漢達","market":"上櫃","industry":"生技醫療","date":"2025-11-19","time":"17:29:18","subject":"代子公司Handa Oncology公告，美國FDA通知治療癌症之505(b)(2)新藥HND-039進入實質審查，完成審查之目標為美國時間115/07/29","clause":"第44款","fact_date":"2025-11-19","cite_as":"公開資訊觀測站重大訊息：漢達（6620），2025-11-19 17:29，「代子公司Handa Oncology公告，美國FDA通知治療癌症之505(b)(2)新藥HND-039進入實質審查，完成」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6917-2025-11-19-1708-1oq3bgh","company_id":"6917","company":"竟天","market":"興櫃","industry":"生技醫療","date":"2025-11-19","time":"17:08:44","subject":"代子公司Andros Pharmaceuticals Pty Ltd公告APC101正式向澳洲Bellberry Human Research Ethics Committee及澳洲TGA申請進行第二b/三期臨床試驗","clause":"第8款","fact_date":"2025-11-19","cite_as":"公開資訊觀測站重大訊息：竟天（6917），2025-11-19 17:08，「代子公司Andros Pharmaceuticals Pty Ltd公告APC101正式向澳洲Bellberry Hum」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7595-2025-11-19-1631-1dg13h8","company_id":"7595","company":"世基生醫","market":"興櫃","industry":"生技醫療","date":"2025-11-19","time":"16:31:08","subject":"公告本公司董事長暨總經理變動事宜","clause":"第6款","fact_date":"2025-11-19","cite_as":"公開資訊觀測站重大訊息：世基生醫（7595），2025-11-19 16:31，「公告本公司董事長暨總經理變動事宜」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-6634-2025-11-19-1607-k50p7y","company_id":"6634","company":"欣耀","market":"興櫃","industry":"生技醫療","date":"2025-11-19","time":"16:07:11","subject":"公告本公司脂肪肝炎新藥SNP-630取得韓國專利","clause":"第44款","fact_date":"2025-11-19","cite_as":"公開資訊觀測站重大訊息：欣耀（6634），2025-11-19 16:07，「公告本公司脂肪肝炎新藥SNP-630取得韓國專利」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4736-2025-11-19-1533-1p5h1m5","company_id":"4736","company":"泰博","market":"上市","industry":"生技醫療","date":"2025-11-19","time":"15:33:16","subject":"公告本公司召開法人說明會相關資訊","clause":"第12款","fact_date":"2025-11-21","cite_as":"公開資訊觀測站重大訊息：泰博（4736），2025-11-19 15:33，「公告本公司召開法人說明會相關資訊」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7851-2025-11-19-1520-1gisbdw","company_id":"7851","company":"慧康生技*-KY","market":"興櫃","industry":"生技醫療","date":"2025-11-19","time":"15:20:46","subject":"公告本公司興櫃掛牌股票每股面額新台幣5元","clause":"第44款","fact_date":"2025-11-19","cite_as":"公開資訊觀測站重大訊息：慧康生技*-KY（7851），2025-11-19 15:20，「公告本公司興櫃掛牌股票每股面額新台幣5元」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7784-2025-11-19-1500-1m4kr97","company_id":"7784","company":"安邦生技*","market":"興櫃","industry":"生技醫療","date":"2025-11-19","time":"15:00:44","subject":"公告本公司晚期大腸直腸癌(mCRC) 一/二期人體臨床試驗完成首位受試者收案。","clause":"第9款","fact_date":"2025-11-19","cite_as":"公開資訊觀測站重大訊息：安邦生技*（7784），2025-11-19 15:00，「公告本公司晚期大腸直腸癌(mCRC) 一/二期人體臨床試驗完成首位受試者收案。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-7790-2025-11-19-1500-pepy2n","company_id":"7790","company":"思必瑞特","market":"興櫃","industry":"生技醫療","date":"2025-11-19","time":"15:00:24","subject":"因應本公司創新板上市申請需要委託簽證會計師出具內控專審報告","clause":"第25款","fact_date":"2025-11-19","cite_as":"公開資訊觀測站重大訊息：思必瑞特（7790），2025-11-19 15:00，「因應本公司創新板上市申請需要委託簽證會計師出具內控專審報告」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"},{"id":"tw-4105-2025-11-19-1431-1ea9xci","company_id":"4105","company":"東洋","market":"上櫃","industry":"生技醫療","date":"2025-11-19","time":"14:31:13","subject":"本公司受邀參加元大證券舉辦之線上法人說明會。","clause":"第12款","fact_date":"2025-11-26","cite_as":"公開資訊觀測站重大訊息：東洋（4105），2025-11-19 14:31，「本公司受邀參加元大證券舉辦之線上法人說明會。」。經 Drugnews 事實帳本收錄：https://drugnews.com.tw/mcp/filings.json"}]}